TSX closed
Loading markets…

Advertisement

Stocks

What's Going On With Medexus Pharmaceuticals Inc Stock Sunday?

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:MDP.TO

Follow MDP

Photos provided by Pexels

Medexus Pharmaceuticals Inc has seen notable price action this week as it navigates through its recent earnings report and ongoing market trends.

This week, shares of Medexus Pharmaceuticals Inc (MDP.TO) closed at C$5.14, reflecting a decline of 1.18% on the day and an 8.07% decrease over the past week. The company has been in the news recently due to its fiscal Q1 2027 results, showcasing strong product-level performance, particularly for its GRAFAPEX (treosulfan) treatment. Despite the positive operational updates, the stock has faced pressure, leading to a significant pullback in its share price.

Investor takeaway: Investors should consider the recent earnings highlights and the company's strategic positioning in the healthcare sector, along with its current technical indicators, as they evaluate potential opportunities in Medexus Pharmaceuticals.

Advertisement

Medexus Pharmaceuticals Inc

MDP.TO

Full stock page →

MDP.TO

Medexus Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
↑ $1.01 (25.38%)
120 day period
$3.82$4.63$5.45Apr 20Jul 15Oct 8

Market cap

$153.04M

52W high

$5.50

52W low

$2.51

1W change

+1.42%

Beta

1.73

Analyst Price Targets

Based on analyst covering MDP · as of Sep 17, 2026

📈

Wall Street analysts forecast MDP stock price to rise 45.3% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$7.25

+45.3% Upside

Current Price

C$4.99

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on MDP's historical volatility

HistoricalForecast68%95%
C$3.30C$4.03C$4.75C$5.48C$6.21C$6.93TodayJun 2Aug 6Oct 8Nov 20Jan 3Feb 15

30-Day Vol

28.5%

Annualized

90-Day Vol

39.1%

Annualized

Trend (90d)

-11.6%

Annualized drift

90d Mean

C$4.79

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$4.92C$4.46 – C$5.43
60 trading daysC$4.85C$4.22 – C$5.58
90 trading daysC$4.79C$4.04 – C$5.68

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Medexus Pharmaceuticals Inc's Stock Performance Summary

With a market cap of approximately C$161.5 million and a year-to-date increase of 62.14%, Medexus is positioned within a highly competitive healthcare market.

Bull case

The bullish sentiment surrounding Medexus is backed by the strong performance of GRAFAPEX, which has shown promising results in recent quarters. Analysts have a positive outlook, with an average price target of C$7.25, indicating a potential upside of over 41% from the current price.

Bear case

On the other hand, the stock's recent downward trend, along with negative profit margins and a high beta of 1.84, suggests increased volatility and risk. Investors should remain cautious, as the stock's performance may be affected by broader market conditions and any delays in product adoption.

Recent Price Action

Advertisement

Medexus Pharmaceuticals Inc (MDP.TO) experienced a closing price of C$5.14, marking a decline of 1.18% for the day and a more substantial drop of 8.07% over the past week. Despite this pullback, the stock has shown a remarkable year-to-date increase of 62.14%, indicating strong performance earlier in the year.

Company News and Earnings Updates

The latest headlines surrounding Medexus include its announcement of fiscal Q1 2027 results, which highlighted the strongest quarter of product-level performance for its GRAFAPEX (treosulfan) treatment to date. This performance has fueled optimism among analysts, who continue to express a bullish outlook for the stock, with an average target of C$7.25. No other major news has surfaced this week, leaving investors to focus on the implications of the earnings report.

Technical Picture

From a technical standpoint, Medexus is trading above its 50-day moving average of C$4.83, which is a positive sign, as it indicates a 6.3% premium over this average. Additionally, the stock is significantly above its 200-day moving average of C$3.61, reflecting a 42.3% increase. The stock is currently trading within 88% of its 52-week range of C$2.51 to C$5.50. The current trading volume of 81,902 shares is approximately 1.95 times the 20-day average volume of 46,085 shares, suggesting heightened trading activity.

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 24, 2026
Last Updated: October 5, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement